Biden Win With Undecided Senate Flips European Market’s Outlook, , on November 7, 2020 at 5:07 am

Financial News
By
On November 7, 2020
In Financial News
Tags:

(Bloomberg) — With Joe Biden on a path to winning the U.S. presidency but control of the Senate still up in the air, investors in European stocks have been forced to review their outlook for some key industries.Market players had spent months positioning for post-election outperformance in European renewable-energy and cyclical stocks, accompanied by weakness in health care and technology. The thinking was that a “blue wave” of Democratic wins would lead to increased fiscal stimulus and support for alternative power, along with higher corporate taxes and possibly legislation that hurt drug companies.Now, Biden looks to be just squeaking out a win, with the outcome in the Senate in limbo until January and the possibility that it remains in Republican hands. With the prospect of divided government, investors are reversing those bets.European technology, consumer and health-care sectors were among the top gainers following the election, while shares in more cyclical industries — banks and energy — declined. This marks a significant shift in market favorites, after tech stocks had slumped 12% in the two months leading up to the vote.“If the outcome is a Biden win with a divided Congress, we would anticipate less drastic policy action,” said Raj Tanna, a portfolio manager at JPMorgan Asset Management. “One could potentially start to see opportunities open up in areas that underperformed in the run-up to the election.”Here are the key European sectors to watch in the aftermath of the U.S. vote:Health CareThe European health-care sector is particularly in focus as a possibly divided Congress would reduce the chances of Biden pursuing legislation that could push drug prices lower and expand access to government health programs.Most large European pharmaceutical groups get a big share of their sales from the U.S. market, with AstraZeneca Plc, Novartis AG, Roche Holding AG and Novo Nordisk ASA all particularly sensitive to U.S. drug-pricing reform. As the prospect of higher U.S. corporate taxes fades, they stand to potentially benefit.“It’s almost the sweet spot for the sector in terms of a little bit of gridlock,” said Dani Saurymper, a fund manager at AXA Investment Managers U.K. Ltd. “Some of the more potentially adverse scenarios are avoided. It might well be that there will still be some form of drug pricing reform on a bipartisan basis, but the likelihood is, if something is going to be bipartisan, whatever comes, it won’t be as bad as what might have come.”Autos and LuxuryEven if Biden’s power is limited by a split Congress, European carmakers are seen as the top winners of his presidency on the reduced risk of a trade war between the U.S. and Europe. The sector has been underperforming the broader benchmark since 2018 when Donald Trump made the threat to impose tariffs on cars imported from the region.Fiat Chrysler Automobiles NV, Michelin and Daimler AG are the most exposed European automakers to the U.S. market, according to UBS Group AG analysts.European top luxury brands, such as LVMH, Remy Cointreau SA and Pernod Ricard SA, are also likely to be relieved about reduced trade tensions. Trump had threatened imports of whiskey, wine, Champagne, handbags and men’s suits.“Trump wanted to slap tariffs on European exporters, and we can reasonably believe that Biden won’t have this kind of approach,” said Florent Delorme, macro strategist at M&G International Investments SA. “He’ll rather seek to strengthen U.S. ties with Europe, which hasn’t been the case at all with Trump.”TobaccoAhead of the U.S. elections, European tobacco was seen as a sector that could suffer from higher U.S. corporate taxes, according to Bloomberg Intelligence analyst Duncan Fox.Scandinavian Tobacco Group A/S, Swedish Match AB, British American Tobacco Plc, and Imperial Brands Plc were among European tobacco firms that rallied on Wednesday as a Democratic sweep of the Senate became more uncertain, reducing the likelihood of aggressive reforms.“A Biden presidency and a Democrat Senate may have been more aggressive in terms of legislation against tobacco” products, such as menthol and flavored cigarettes and potentially next-generation products, said Richard Buxton, head of strategy, U.K. alpha at Jupiter Asset Management. Without a sweep for the Democrats, “there won’t be the scope to do much radical” reforms, he said.Renewable EnergyBiden’s plans to spend $2 trillion on clean energy and fighting climate change may be at risk under a Republican Senate. European renewable-energy stocks, such as Vestas Wind Systems A/S and Siemens Gamesa Renewable Energy SA, declined on Wednesday.JPMorgan U.S. alternative energy analyst Paul Coster said that Biden “will need to collaborate with a split Congress, and implementation of a Green New Deal in the next two years looks unlikely.”However, alternative energy stocks bounced back on Thursday as some market players speculated that Biden will be able to use executive power and federal regulation to push clean energy use even with a divided Congress.TechnologyAhead of the U.S. elections, UBS strategists saw European technology stocks, and especially hardware companies, at risk from higher U.S. corporate taxes because the latter get 29% of revenue from the country. If the Senate turns Republican, this threat will likely be removed.According to Lars Kreckel, global equity strategist at Legal & General Investment Management, a split Congress would also reduce the likelihood of aggressive regulatory reforms in the tech sector.Nataliia Lipikhina, global equities strategist at JPMorgan Private Bank, favors European technology companies on the low interest rate environment and on such drivers as the transition to electric vehicles and 5G technology.CyclicalsCyclical European stocks underperformed after the U.S. elections on concern about less-generous fiscal stimulus if the Republicans control the Senate.Still, some market players, including Manulife Investment Management’s Nathan Thooft and Eaton Vance’s Chris Dyer, expect the size of fiscal stimulus to be substantial enough to support an economic recovery. A focus on infrastructure spending should also be positive for European construction and infrastructure stocks with exposure to the U.S. market, such as CRH Plc.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Biden Win With Undecided Senate Flips European Market’s Outlook(Bloomberg) — With Joe Biden on a path to winning the U.S. presidency but control of the Senate still up in the air, investors in European stocks have been forced to review their outlook for some key industries.Market players had spent months positioning for post-election outperformance in European renewable-energy and cyclical stocks, accompanied by weakness in health care and technology. The thinking was that a “blue wave” of Democratic wins would lead to increased fiscal stimulus and support for alternative power, along with higher corporate taxes and possibly legislation that hurt drug companies.Now, Biden looks to be just squeaking out a win, with the outcome in the Senate in limbo until January and the possibility that it remains in Republican hands. With the prospect of divided government, investors are reversing those bets.European technology, consumer and health-care sectors were among the top gainers following the election, while shares in more cyclical industries — banks and energy — declined. This marks a significant shift in market favorites, after tech stocks had slumped 12% in the two months leading up to the vote.“If the outcome is a Biden win with a divided Congress, we would anticipate less drastic policy action,” said Raj Tanna, a portfolio manager at JPMorgan Asset Management. “One could potentially start to see opportunities open up in areas that underperformed in the run-up to the election.”Here are the key European sectors to watch in the aftermath of the U.S. vote:Health CareThe European health-care sector is particularly in focus as a possibly divided Congress would reduce the chances of Biden pursuing legislation that could push drug prices lower and expand access to government health programs.Most large European pharmaceutical groups get a big share of their sales from the U.S. market, with AstraZeneca Plc, Novartis AG, Roche Holding AG and Novo Nordisk ASA all particularly sensitive to U.S. drug-pricing reform. As the prospect of higher U.S. corporate taxes fades, they stand to potentially benefit.“It’s almost the sweet spot for the sector in terms of a little bit of gridlock,” said Dani Saurymper, a fund manager at AXA Investment Managers U.K. Ltd. “Some of the more potentially adverse scenarios are avoided. It might well be that there will still be some form of drug pricing reform on a bipartisan basis, but the likelihood is, if something is going to be bipartisan, whatever comes, it won’t be as bad as what might have come.”Autos and LuxuryEven if Biden’s power is limited by a split Congress, European carmakers are seen as the top winners of his presidency on the reduced risk of a trade war between the U.S. and Europe. The sector has been underperforming the broader benchmark since 2018 when Donald Trump made the threat to impose tariffs on cars imported from the region.Fiat Chrysler Automobiles NV, Michelin and Daimler AG are the most exposed European automakers to the U.S. market, according to UBS Group AG analysts.European top luxury brands, such as LVMH, Remy Cointreau SA and Pernod Ricard SA, are also likely to be relieved about reduced trade tensions. Trump had threatened imports of whiskey, wine, Champagne, handbags and men’s suits.“Trump wanted to slap tariffs on European exporters, and we can reasonably believe that Biden won’t have this kind of approach,” said Florent Delorme, macro strategist at M&G International Investments SA. “He’ll rather seek to strengthen U.S. ties with Europe, which hasn’t been the case at all with Trump.”TobaccoAhead of the U.S. elections, European tobacco was seen as a sector that could suffer from higher U.S. corporate taxes, according to Bloomberg Intelligence analyst Duncan Fox.Scandinavian Tobacco Group A/S, Swedish Match AB, British American Tobacco Plc, and Imperial Brands Plc were among European tobacco firms that rallied on Wednesday as a Democratic sweep of the Senate became more uncertain, reducing the likelihood of aggressive reforms.“A Biden presidency and a Democrat Senate may have been more aggressive in terms of legislation against tobacco” products, such as menthol and flavored cigarettes and potentially next-generation products, said Richard Buxton, head of strategy, U.K. alpha at Jupiter Asset Management. Without a sweep for the Democrats, “there won’t be the scope to do much radical” reforms, he said.Renewable EnergyBiden’s plans to spend $2 trillion on clean energy and fighting climate change may be at risk under a Republican Senate. European renewable-energy stocks, such as Vestas Wind Systems A/S and Siemens Gamesa Renewable Energy SA, declined on Wednesday.JPMorgan U.S. alternative energy analyst Paul Coster said that Biden “will need to collaborate with a split Congress, and implementation of a Green New Deal in the next two years looks unlikely.”However, alternative energy stocks bounced back on Thursday as some market players speculated that Biden will be able to use executive power and federal regulation to push clean energy use even with a divided Congress.TechnologyAhead of the U.S. elections, UBS strategists saw European technology stocks, and especially hardware companies, at risk from higher U.S. corporate taxes because the latter get 29% of revenue from the country. If the Senate turns Republican, this threat will likely be removed.According to Lars Kreckel, global equity strategist at Legal & General Investment Management, a split Congress would also reduce the likelihood of aggressive regulatory reforms in the tech sector.Nataliia Lipikhina, global equities strategist at JPMorgan Private Bank, favors European technology companies on the low interest rate environment and on such drivers as the transition to electric vehicles and 5G technology.CyclicalsCyclical European stocks underperformed after the U.S. elections on concern about less-generous fiscal stimulus if the Republicans control the Senate.Still, some market players, including Manulife Investment Management’s Nathan Thooft and Eaton Vance’s Chris Dyer, expect the size of fiscal stimulus to be substantial enough to support an economic recovery. A focus on infrastructure spending should also be positive for European construction and infrastructure stocks with exposure to the U.S. market, such as CRH Plc.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Follow Us

Market Coverage